Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

@article{Long2015DabrafenibAT,
  title={Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial},
  author={Georgina V. Long and Daniil Stroyakovskiy and Helen J. Gogas and Evgeny Levchenko and Keith Flaherty},
  journal={The Lancet},
  year={2015},
  volume={386},
  pages={444-451}
}
BACKGROUND Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free survival compared with dabrafenib and placebo in patients with BRAF Val600Lys/Glu mutation-positive metastatic melanoma. The study was continued to assess the secondary endpoint of overall survival, which we report in this Article. METHODS We did this double-blind phase 3 study at 113 sites in 14 countries. We enrolled previously untreated patients with BRAF Val600Glu or… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 285 CITATIONS, ESTIMATED 46% COVERAGE

Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAFV600 Mutation

  • Targeted Oncology
  • 2016
VIEW 24 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.

  • Expert opinion on pharmacotherapy
  • 2015
VIEW 22 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

  • American journal of clinical dermatology
  • 2018
VIEW 14 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 16 Highly Influenced Citations

  • Averaged 64 Citations per year from 2017 through 2019

Similar Papers

Loading similar papers…